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pregnancy populationThe successful delivery of a normal healthy baby is the goal of all
pregnant women. The introduction of ultrasound, chorionic villus
sampling, and amniocentesis has made it possible to detect fetal
structural defects and fetal chromosome abnormalities [1]. However,
the possibility of membrane rupture, infection, and subsequent
abortion cannot be totally eliminated during the chorionic villus
sampling or amniocentesis procedures. Therefore, the development
of an effective screening algorithm to identify better women at
high risk of detectable fetal abnormalities in concert with the advent
of safer and more accessible diagnostic tests is a goal of physicians,
technicians, and pregnant women. Noninvasive prenatal testing
(NIPT) and the detection of circulating fetal cell-free nucleic acids
(cfna)may fulﬁll the aforementioned criteria because the riskof preg-
nancy loss can be avoided [2]. The current issue of the Taiwanese Jour-
nal of Obstetrics and Gynecology includes an article that describes the
experience of using NIPT for prenatal diagnosis [3]. The special ﬁnd-
ings of this study included (1) 88.4% of women in Taiwan were clas-
siﬁed as a high-risk population; (2) in Taiwan, 94.3% of pregnancies
were singleton pregnancies, and the remaining pregnancies were
twin and triplet pregnancies; (3) 18.3% of Taiwanese women became
pregnant using an assisted reproduction technique; and (4) the
positive NIPT rate was 1.18% in Taiwan. The other results were (1)
the study was totally free of false-negative reports; (2) the risk of
false-positive results was low; (3) a high proportion of
discordant sex chromosomal aneuploidies were associated with
NIPT; and (4) there was a 100% sensitivity rate and a high speciﬁcity
rate (>99%).
We applaud the publication of the article by Li et al [3] because
very rapid DNA sequencing and computer hardware and software
capable of matching hundreds of millions of DNA fragments and
sequences within hours have made NIPT possible [4]. In addition,
negative predictive values of 100% in combination with signiﬁ-
cantly and substantially lower false-positive rates with NIPT
(<1%) augurs well for pregnant women: a negative NIPT result
obviates the need for further invasive procedures and the
discomfort and risk to the pregnancy that is incurred by such pro-
cedures. However, there are many issues that require further
exploration.
First, is using NIPT as a tool for prenatal diagnosis cost-effective?
Should it be a ﬁrst-line or second-line test? Neyt et al [5] performed
a costeconsequences analysis and found that introducing NIPT as a
ﬁrst- or second-line diagnostic tool reduces harm by decreasing the
number of procedure-related miscarriages after invasive testing. In
addition, the reimbursement of NIPT as a second-line triage test did
not increase the short-term screening costs. However, offering and
reimbursing NIPT as a ﬁrst-line treatment to all pregnant women ishttp://dx.doi.org/10.1016/j.tjog.2014.12.004
1028-4559/Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Publishedpreferred in the long term because it would also lead to fewer cases
of trisomy 21 [5].
Second, the use of NIPT for twins or more remains controversial.
A recent report [6] from Belgium showed that themedian fetal frac-
tion was signiﬁcantly lower in twins than in singletons (8.7% vs.
11.7%, respectively), which suggests that NIPT for twins has a higher
failure rate and lower detection rate than for singletons. However,
the authors of that study still concluded that twin screening by
NIPT is feasible.
Third, concerns about the false-positive rate of NIPT are always
present, especially for pregnant women who are originally classi-
ﬁed as “low risk.” The guidelines published by the American Col-
lege of Obstetricians and Gynecologists still do not recommend
using NIPT for screening low-risk women because of insufﬁcient
evaluation of cfna technologies in the screening of such pregnan-
cies; this also applies to twin pregnancies [7]. Many uncertainties
could not be totally avoided in the report by Li et al [3], although
their ﬁndings corroborate a previous feasibility report of applying
NIPT for high-risk pregnant women [8]. However, the risk-beneﬁt
ratio should be balanced carefully since this tool relied on high
sensitive rate to detect the disease and high speciﬁc rate to
conﬁrm the disease. If current screening methods do not satisfy
the above-mention with high sensitive and speciﬁc rate, or
continue to fail to enhance the outcomes of screened fetuses,
why should we do this? Therefore, we are happy to publish this
article and hope that a large-scale study will be performed in
the future.
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